| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidateCandidate's Name (Vageli), PhDResearch ScientistNew Haven, CT, USAEMAIL AVAILABLEPHONE NUMBER AVAILABLEProfileExperienced senior-level research scientist with a robust background in Molecular Oncology, Biotechnology, Cancer Biology, Cellular Biology, Molecular Pathology and Histopathology. Over 20 years of expertise in exploring human diseases, and related biomarkers as potential diagnostic markers or targets for therapy. Extensive experience in clinical studies, biorepository, cancer modeling, translational medicine, histopathology, and using microscopy, image analyses, molecular analyses, ligand assays, genetics, and other innovative technologies. Proven track record in leading research projects securing funding and publishing extensively. Over twenty years of teaching, experience in biomedical science and laboratory medicine. Strong in leadership by mentoring and training staff and students, laboratory and project management, clinical operations and cross-functional collaboration. Currently on training of SAS.Work ExperienceResearch Scientist/ Associate Research ScientistYale University School of Medicine, New Haven, CTSeptember 2013 PresentLead the "Neoplasia" group, establishing in vitro (cell culturing), and in vivo (mouse) models, translational and clinical studies, exploring inflammatory and cancer related signaling pathways and targets for future therapeutic applications in cells, biospecimens (tissue, blood and saliva).Design (IRB protocols), and conduct translational and clinical studies, by selecting and follow up patients (epic) and healthy individuals and analyzing clinical specimens, to discover molecular biomarkers for cancer disease.Design research strategies and perform nucleic acid (DNA, mRNA, miRNA) analyses, by qPCR, electrophoreses, NGS, spatial gene expression analyses etc., protein analyses (Western blot, ELISA, immunoassays) in cells, tissues and their extracts, knockout genes, cell proliferation assays, drug applications, histological staining, microscopy and image analyses, differential expression analyses, functional analyses (IPA), statistical analyses (GraphPad etc.).Management of laboratory (equipment, supplies, staff, safety etc.), agenda, briefings and presentations.Leadership by mentoring and training research staff and postgraduate students, medical students, postdoctoral associates, medical residents.Conducted a comprehensive literature review and analysis to identify gaps in current research and create a roadmap for future workDesign and conduct experiments to test hypotheses and validate results.Create detailed investigative plans and reports, ensuring the successful conclusion of investigations within budget and on time.Collaborate with faculty on a variety of research projects, contributing to a successful grant proposal.Design and conduct experiments, ensuring timely and budget-compliant completion.Secure multiple research projects and published over 50 peer-reviewed articles.Special Teaching & Research Staff, Molecular Oncology and HistopathologyUniversity of Thessaly Medical School, Larissa, GreeceDecember 2002 September 2013Established diagnostic and research laboratory of molecular histopathologyDirected diagnostic tests in Molecular Pathology.Directed clinical studies, using histopathological (IHC, FISH, histological staining, microscopy, image analyses) and molecular analyses (qPCR, targeted sequencing), in human diseases, contributing to advancements in breast cancer and non-small cell lung carcinoma.Proposed a potential role of mismatch repair gene phenotypes in the prognosis of epithelial cancers.Collaborated with interdisciplinary teams to enhance research outcomes and clinical applications.Developed and delivered lectures on molecular oncology and histopathology to medical studentsLecturer, HistopathologyUniversity of Thessaly Medical School, Larissa, Greece2005 2006Conducted lectures and practical sessions in molecular biology and pathology.Supervised undergraduate research projects, fostering a research-oriented learning environment.Facilitated group discussions and activities to promote critical thinking and collaborative learningCoordinated with other faculty members to develop and update course curriculum to align with current industry trends and best practices.Developed and updated course curriculum.Lecturer, HistopathologySchool of Health Professions, Higher Technological Education Institution, Larissa, GreeceJanuary 2004 December 2012Conducted lectures and practical sessions in molecular biology and histopathology (Basic and Specific).Supervised undergraduate research projects ((Diploma thesis).Developed and updated course curriculum.Clinical experienceAssociate Research Scientist/Research Scientist, Coordinator-Assistant of Yale Head and Neck Biorepository (SPORE)Patient enrollment (epic)Human specimen collection (tissue specimens, blood, and saliva)Specimens archiving (liquid nitrogen, -80C, pathology)Specimens analysis (submission to YCGA)Specimens distribution (shipment to other institutions, such as UNC) as part of ongoing chemotherapeutic clinical trials.Special Laboratory & Research Staff, Molecular PathologyUniversity and General Hospital of Larissa, Thessaly, Greece2004 2013Established the 1st diagnostic and research laboratory of molecular histopathology in the Medical School of Thessaly, Greece (2002-2009)Diagnostic molecular pathology tests.oPrepared and organized samples for molecular pathology testingoRecorded and documented laboratory data and results in an accurate and timely manneroDeveloped a method of analysis of samples that yielded reliable and accurate resultsoResponsible for creating and maintaining inventories, contacting suppliers, ordering, and budget preparation.Operated and maintained laboratory equipment, ensuring safety protocols and quality standards were met.Proposed a potential role of mismatch repair gene phenotypes in the prognosis of epithelial cancers.Directed clinical research studies in human diseases, contributing to advancements in breast cancer and non-small cell lung carcinoma.Developed and delivered lectures on molecular oncology and histopathology to medical students.Collaborated with interdisciplinary teams to enhance research outcomes and clinical applications.Intern, Clinical Microbiology & BiochemistryArmy Hospital-NIMTS-Athens, Greece1991Prepared and organized samples for testing and analysisRecorded and documented laboratory data and results in an accurate and timely mannerDeveloped a method of analysis of samples that yielded reliable and accurate resultsOperated and maintained laboratory equipment, ensuring safety protocols and quality standards were met.EducationPhD in Molecular Oncology & BiotechnologyUniversity of Crete, School of Health Sciences, Faculty of MedicineJune 1994 November 1998Postgraduate Research Scholarship in Radiation Biology & PhysicsInstitute of Radiation and Radio-predict Products (I.R.R.P),National Centre for Scientific Research Demokritos, GreeceMarch 1990 to October 1990BSc in Biology ScienceUniversity of Patras, School of Natural SciencesSeptember 1985 October 1989AwardsOhse Research Award, Yale School of Medicine, Department of SurgeryJanuary 2015To explore the effect of laryngopharyngeal reflux induced NF-B activation in pre-malignant transformation of in vivo hypopharyngeal mucosa.Ohse Research Award, Yale School of Medicine, Department of Surgery.January 2014To explore the in vitro effect of laryngopharyngeal reflux induced NF-B activation and its role in Laryngopharyngeal carcinogenesis.1st Honor for best scientific work Presentation-Hellenic Thoracic Society.2013Mismatch DNA repair expression profiles correlated with miR-422a, miR-21 and miR-155 levels in non-small cell lung carcinomasPostgraduate Research Scholarship in Radiation Biology & PhysicsInstitute of Radiation and Radio-predict Products (I.R.R.P),National Centre of Science Research-Demokritos, GreeceJanuary 1990To receive training in radiation biology, nuclear chemistry, radiation physics, biostatistics, and MRI-CT diagnostics.SkillsMolecular BiologyMolecular OncologyMolecular Pathology & HistopathologyCancer BiologyCell BiologyProtein analysesLigand assaysNucleic acid analysesCell cultureMouse modelsClinical Research StudiesPharmacological StudiesProject LeadershipProject ManagementProject CoordinationLaboratory ManagementSenior LeadershipHigher Education TeachingProject coordinationMicrobiologyResearch & DevelopmentGLPAseptic TechniquePresentation SkillsWriting SkillsMicroscopyGCPData AnalysisWestern BlotELISAPCRNGSStem cellsAnimalComputer NetworkingProgram DevelopmentRecruitingQuality AssuranceClinical TrialsSAS (under training)MembershipsResearch Member of Yale Cancer Centre (Cancer Signaling Network)March 2024 to Presenthttps://www.yalecancercenter.org/Active member of American Association for Cancer Research (AACR)December 2023 to Presenthttps://www.aacr.org/Associate Member of the World Academy of Sciences2019 to Presenthttp://www.worldacademyofsciences.com/members.htmlAssociate Scientific member of American Head and Neck Society (AHNS)2021 to Presenthttps://www.ahns.info/PanHellenic Union of Bioscientists1989 to Presenthttps://www.pev.grSymposium Chair-Invited Speaking EngagementsChair, 24th World Congress on Advances in Oncology, Greece, 2019Chair, 23rd World Congress on Advances in Oncology, Greece, 2018Chair, 21st World Congress on Advances in Oncology, Greece, 2016Lecture/Oral presentations/Posters & Symposia(selected from a total of 38)Vageli DP, Doukas GP, Judson BL. Saliva IL6 upregulation as a potential indicator of tobacco-smoke-associated OSCC and disease progression and the association of saliva RELA upregulation with OSCC local Invasion in non-smokers. 12th Annual Symposium on Global Cancer Research (May 6-9 2024).Vageli DP, Doukas GP, Judson BL Discovering novel and unique saliva and serum miRNA and mRNA signatures for oral cancer detection using whole transcriptome and small non-coding RNA sequencing: prediction of their association with PI3K/AKT pathway. 12th Annual Symposium on Global Cancer Research (May 6-9 2024).Vageli DP, Doukas PG, Judson BL. A novel saliva miRNA panel of promising diagnostic biomarkers for oral cancer: the association of miR-21 with smoking history. AACR-AHNS conference July 7-8, 2023, Palais des congrs de Montral, Monteal, GC, Canada.Vageli DP, Doukas SG, Sasaki CT. (121) In vivo topical application of BAY 11-7082 prevents the acidic bile-induced mRNA and miRNA oncogenic phenotypes, in exposed murine hypopharyngeal mucosa. International Journal of Molecular Medicine 42, S10-S10. 23rd World Congress on Advances in Oncology and 22nd International Symposium on Molecular Medicine 2018; September 22; Athens, Greece.Vageli D, Sasaki CT. (307) In vitro and in vivo models for gastro-duodenal fluid induced nuclear kappaB activation and its role in laryngopharyngeal carcinogenesis. International Journal of Molecular Medicine 38, S56-S56. 21st World Congress on Advances in Oncology and 19th International Symposium on Molecular Medicine 2016; October 07; Athens, Greece.Vageli D, et al. (4639) Correlation of miR-422a, miR-21 and miR-155 analysis with hMSH2 and hMLH1 mRNA expression profiles in non-small cell lung carcinomas and their adjacent normal tissues. Session 441: Biology and molecular pathology of lung cancer. ERS Annual Congress 2013; September 7-11; Barcelona, Spain.Vageli D, et al. (437) Determination of hypoxia effects to hMSH2 and hMLH1, DNA repair gene expression in non-small cell lung carcinomas. The 13th World Congress on Advances in Oncology and 11th International Symposium on Molecular Medicine 2008; October 9-11; Hersonissos, Crete, Greece.Mentor (selected from a total of 22)April 2024 (Poster presentation) Oral Premalignant lesions-associated Saliva and Serum mRNA and miRNA Profiles by Next-generation Sequencing: A Pilot Study. Surgery Research Day, Yale School of Medicine.April 2024 (Poster presentation) Identification of novel saliva and serum miRNA and mRNA signatures for oral cancer detection using whole transcriptome and small non-coding RNA sequencing: prediction of their association with the PI3K/AKT pathway. Surgery Research Day, Yale School of Medicine.April 2020 (Grand Rounds - Showcase) Long-term exposure of laryngopharyngeal mucosa to acidic bile is carcinogenic Surgery Research Day, Yale School of Medicine.June 2018 (Oral presentation) The effect of pH on bile-induced transcriptional activation of mRNA oncogenic phenotype in human hypopharyngeal primary cells Resident Research Day, Yale School of Medicine, Department of Surgery (Otolaryngology).June 2017 (Oral presentation) An in vivo model of acid as a dependent factor in bile-related effect in laryngopharyngeal mucosa Resident Research Day, Yale School of Medicine, Department of Surgery (Otolaryngology).Composing and submitting funded grant proposalsJanuary 2015: Ohse Research Award, Yale School of Medicine, Department of Surgery (PI: D. Vageli) The effect of laryngopharyngeal reflux induced NF-B activation in the pre-malignant transformation of in vivo hypopharyngeal mucosa.January 2014: Ohse Research Award, Yale School of Medicine, Department of Surgery. (PI: D. Vageli) The in vitro effect of laryngopharyngeal reflux induced NF-B activation and its role in Laryngopharyngeal carcinogenesis.Composing and submitting unfunded grant proposals:March 2024 Resubmission R01 /NCI/DCP/Cancer Biomarkers Research Group. Role: PI (Co-PI/M: Dr. Benjamin L. Judson) Title: Non-invasive molecular biomarkers for detection and prognosis of oral premalignant and monitoring PML (2,500,000/for 5 years)February 2023: R01 /MCDC (Molecular Cancer Diagnosis and Classification Study Section)Role: Co-PI (PI/Mentor: Dr. Benjamin L. Judson) Title: Non-invasive molecular biomarkers for detection of oral high-risk premalignant and early malignant lesion.October 2023 R03/NCI/DCP/Role PI (Co-PI/Mentor: Dr. Benjamin L. Judson) PAR23-058 Discovering saliva microRNA profile for the detection of laryngeal cancer (100,000/ 2 years)May 2022: Yale SPORE in Head & Neck Cancers Development Research Program / Role: Co-Investigator (PI: Benjamin L. Judson) / Title: Combined saliva and serum miRNA profiles as diagnostic biomarkers in HPV-negative HNSCC.January 2021: AHNS Pilot Grant / Role: PI (Mentor: Sasaki CT) / An in vivo model of pepsin-induced hypopharyngeal carcinogenesis and the role of NF-kB as a key mediator of pepsin-induced anti-apoptotic function.October 2020: R01 to NCI / NIDCR /Role Co-Investigator (PI: Sasaki CT) / Title: Establishing a 2-hit convergence model of bile-induced squamous cell carcinogenesis in hypopharynx and esophagus.January 2016 & 2017. R01 to NCI / Role: Co-Investigator (PI: Sasaki CT) / Title: Gastroduodenal reflux induced neoplastic transformation of hypopharyngeal mucosaFebruary 2015: Pilot Award Yale Cancer Center (PI: Sasaki CT). Carcinogenic effect of individual or combined risk factors, via NF-B activation, in laryngopharyngeal and esophageal mucosa: relationships with specific miRNA profiling.Journal Service:Editorial (2022-present)Associate Editor: Journal of Molecular Histology (Springer Nature). 2024Editor in Current Oncology (MDPI) (ISSN 1718-7729) 2022. Section: Head and Neck OncologySpecific issue: Advances in Squamous Cell Carcinoma of Head and Neck (viewed by 16716) https://www.mdpi.com/journal/curroncol/special_issues/advances_hnsccReviewer 2015-present (>30 manuscripts in more than 14 journals):Nature Communications Medicine (i.f.: 16.7); Int. J. Mol. Sci. (MDPI) (i.f.: 5.6); Int J Mol Med (i.f.: 5.4); Journal of Cellular and Molecular Medicine (i.f.: 5.3); Int J Oncol (i.f. 5.2); Scientific Reports (i.f.: 5); European Journal of Pharmacology (i.f.: 4.4); Oncology Reports (i.f.: 4.2); Frontiers in Bioscience-Landmark (FBL) (i.f.: 3.9); Oncotarget (i.f.: 2.5-3.3); OncoTargets and Therapy (i.f.: 3.1); Medicina (MDPI) (i.f.: 2.9); Oncology Letters (i.f.: 2.9); Experimental and Therapeutic Medicine (i.f.: 2.7) etc.Publications (selected peer-reviewed publications from a total of 55)1.Vageli DP, et al. Laryngeal rare benign non-epithelial tumors and sarcomas emphasizing on chondrosarcomas: a literature review and a case presentation. Pathology - Research and Practice 2024 (online July 30); 155512, https://doi.org/10.1016/j.prp.2024.1555122.Vageli DP, et al. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in Glioblastoma Multiforme: going beyond pathologic implications. Oncology Res. 2024: 32(8):1239-1256 https://doi.org/10.32604/or.2024.0521303.Vageli DP, et al. Novel non-invasive molecular signatures for oral cavity cancer, by whole transcriptome and small non-coding RNA sequencing analyses: Predicted association with PI3K/AKT/mTOR pathway. Cancer Med. 2024. https://doi.org/10.1002/cam4.73094.Vageli DP, et al A Novel Saliva and Serum miRNA Panel as a potential useful index for Oral Cancer and the Association of miR-21 with smoking history: a pilot study. Cancer Prev Res (Phila). 2023. DOI: PHONE NUMBER AVAILABLECAPR-23-0219.5.Shah R, Tyagi S, Vageli DP, Judson B. Cost-effectiveness of hypothetical miRNA biomarker testing for post-treatment surveillance of HPV-negative OPSCC. Oral Oncology Reports 2023;8: 100122. https://doi.org/10.1016/j.oor.2023.100122.6.Doukas SG, Doukas PG, Vageli DP, et al. Gastric cancer after Bariatric Bypass Surgery. Do they relate? (A Systematic Review). Obes Surg. 2023. DOI: 10.1007/sPHONE NUMBER AVAILABLE7.Vageli D, et al. Laminin Immunostaining in Biopsies as a Useful Biomarker of Early Invasion in Actinic Cheilitis and Differential Diagnosis Between Actinic Cheilitis and Lip Cancer: New Insights. Head Neck Pathol. 2023. DOI: 10.1007/sPHONE NUMBER AVAILABLE-y.8.Cicek B, Hacimuftuoglu A, Kuzucu M, Cetin A, Yeni Y, Genc S, Yildirim S, Bolat I, Kantarci M, Gul M, Hayme S, Matthaios D, Vageli DP, et al. Sorafenib Alleviates Inflammatory Signaling of Tumor Microenvironment in Precancerous Lung Injuries. Pharmaceuticals (Basel). 2023. DOI: 10.3390/ph16020221.9.Genc S, Yagci T, Vageli DP, et al. Exosomal MicroRNA-223, MicroRNA-146, and MicroRNA-21 Profiles and Biochemical Changes in Laryngeal Cancer. ACS Pharmacol Transl Sci. 2023. DOI: 10.1021/acsptsci.3c00038.10.Vageli DP, et al. Targeting STAT3 prevents bile reflux-induced oncogenic molecular events linked to hypopharyngeal carcinogenesis. J Cell Mol Med. 2022. DOI: 10.1111/jcmm.17011.11.Vageli DP, et al. Noxious Combination of Tobacco Smoke Nitrosamines with Bile, Deoxycholic Acid, Promotes Hypopharyngeal Squamous Cell Carcinoma, via NFB, In Vivo. Cancer Prev Res (Phila). 2022. DOI: PHONE NUMBER AVAILABLECAPR-21-0529.12.Doukas SG, Vageli DP, et al. The Effect of Tobacco Smoke N-Nitrosamines, NNK and NDEA, and Nicotine, on DNA Mismatch Repair Mechanism and miRNA Markers, in Hypopharyngeal Squamous Cell Carcinoma: An In Vivo Model and Clinical Evidence. Curr Oncol. 2022. DOI: 10.3390/curroncol29080437.13.Vageli DP, et al. Bile reflux and hypopharyngeal cancer (Review). Oncol Rep. 2021. DOI: 10.3892/or.2021.8195.14.Sasaki CT, Hajek M, Doukas SG, Vageli DP. The role of bile reflux and its related NF-B activated pathway in progression of hypopharyngeal squamous cell cancer. Oral Oncol. 2020. DOI: 10.1016/j.oraloncology.PHONE NUMBER AVAILABLE15.Doukas SG, Vageli DP, et al. The Effect of NNK, A Tobacco Smoke Carcinogen, on the miRNA and Mismatch DNA Repair Expression Profiles in Lung and Head and Neck Squamous Cancer Cells. Cells. 2020. DOI: 10.3390/cells9041031.16.Vageli DP, et al. The temporal effects of topical NF-B inhibition, in the in vivo prevention of bile-related oncogenic mRNA and miRNA phenotypes in murine hypopharyngeal mucosa: a preclinical model. Oncotarget. 2020. DOI: 10.18632/oncotarget.27706.17.Tsatsakis A, Calina D, Falzone L, Petrakis D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, Doukas PG, Kavali L, Bukhari A, Gadiparthi C, Vageli DP, et al. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol. 2020. DOI: 10.1016/j.fct.PHONE NUMBER AVAILABLE18.Vageli DP, et al. Curcumin prevents the bile reflux-induced NF-B-related mRNA oncogenic phenotype, in human hypopharyngeal cells. J Cell Mol Med. 2018. DOI: 10.1111/jcmm.13701.19.Vageli DP, et al. Inhibition of NF-B prevents the acidic bile-induced oncogenic mRNA phenotype, in human hypopharyngeal cells. Oncotarget. 2017. DOI: 10.18632/oncotarget.23143.20.Sasaki CT, Vageli DP. miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo. Neoplasia. 2016. DOI: 10.1016/j.neo.2016.04.007.21.Vageli DP, et al. Gastro-duodenal fluid induced nuclear factor-appaB activation and early pre-malignant alterations in murine hypopharyngeal mucosa. Oncotarget. 2016. DOI: 10.18632/oncotarget.6824.22.Vageli DP, et al. Effect of TNF- inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques. Exp Ther Med. 2015. DOI: 10.3892/etm.2015.2688.23.Vageli DP, et al. Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium. Oncol Lett. 2013. DOI: 10.3892/ol.2012.979.24.Vageli DP, et al. hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: correlation with patient survival and response to adjuvant chemotherapy treatment. Int J Biol Markers. 2013. DOI: 10.5301/JBM.2012.9420.25.Ioannou M, Papamichali R, Kouvaras E, Mylonis I, Vageli D, et al. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung. 2009. DOI: 10.1007/sPHONE NUMBER AVAILABLE-z.26.Vageli D, et al. Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas. Lung Cancer. 2009. DOI: 10.1016/j.lungcan.2008.09.0.27.Vageli D, et al. High-risk human papillomavirus (HPV) in parotid lesions. Int J Biol Markers. 2007. DOI: PHONE NUMBER AVAILABLE00401.28.Kostopoulou E, Vageli D, et al. Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR. Breast. 2007. DOI: 10.1016/j.breast.2007.05.008.29.Vageli D, et al. Microsatellite instability and loss of heterozygosity at the MEN1 locus in lung carcinoid tumors: a novel approach using real-time PCR with melting curve analysis in histopathologic material. Oncol Rep. 2006. DOI: 10.3892/or.15.3.557.30.Vageli D, et al. Transcriptional activation of hTERT in breast carcinomas by the Her2-ER81-related pathway. Oncol Res. 2009. DOI: PHONE NUMBER AVAILABLE12507.31.Vageli D, et al. Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett. 1996. DOI: PHONE NUMBER AVAILABLE(96)04372-8.32.Kotsinas A, Vageli D, et al. Genomic instability and loh at 2 polymorphic sites in the h-ras1 gene. Int J Oncol. 1994. DOI: 10.3892/ijo.5.6.1249.Peer-Reviewed Educational Materials33.Book2: Vageli D., Specific Histopathology. 1st ed. Athens, Greece: Beta Medical Publishers Ltd., ISBN: 978-960-452-092-3; 2010. 324p. https://betamedarts.gr/vivlia/iatrika/anatomikh-kyttarologia-istologia-pathologikh-anatomikh/eidikh-istopathologia/34.Book1: Vageli D., Basic Histopathology, 1st ed. Athens, Greece: Beta Medical Publishers Ltd, ISBN: 978-960-452-069-5; 2009. 111p. https://betamedarts.gr/vivlia/iatrika/anatomikh-kyttarologia-istologia-pathologikh-anatomikh/genikh-istopathologia/Under peer review article35.Vageli DP, et al. The Role of HF-1 and VEGF as Biomarkers in the Prognosis and Evaluation of Treatment Efficacy of Atherosclerosis: A Systematic Review of the Literature. Frontiers in Bioscience Landmark 2024 (under review) |
